Table 1 Clinical features of patients in the 2D-DIGE discovery experiment
Clinical features | Responders (n = 11) | Non responders (n = 12) |
|---|---|---|
Age (range, years) | 61 (47-74) | 58 (29-71) |
Gender (male/female) | 7/4 | 4/8 |
Site | ||
Ascending colon | 1 (9.%) | 2 (16.7%) |
Descending colon | 3 (27.3%) | 1 (8.3%) |
Tranverse colon | 0 | 1 (8.3%) |
Sigmoid colon | 5 (45.5%) | 4 (33.3%) |
Rectum | 2 (18.2%) | 4 (33.3%) |
Stage of CRC at diagnosis | ||
Stage I | 0 | 0 |
Stage II | 0 | 0 |
Stage III | 1 (9.1%) | 0 |
Stage IV | 10 (90.9%) | 12 (100%) |
Differentiation | ||
Well | 1 (9.1%) | 1 (8.3%) |
Moderately | 8 (72.7%) | 5 (41.7%) |
Poorly | 1 (9.1%) | 2 (16.7%) |
Unknown | 1 (9.1%) | 4 (33.3%) |
Previous chemotherapy in Neoadjuvant/Adjuvant setting | ||
Yes | 0 | 0 |
No | 11 (100%) | 12 (100%) |
Chemotherapy for mCRC | ||
FOLFOX/FLOX | 4 (36.4%) | 6 (50%) |
FOLFIRI | 2 (18.2%) | 0 |
Xelox | 4 (36.4%) | 6 (50%) |
5FU/Xeloda | 1 (9%) | 0 |
Maintenance bevacizumab | ||
Yes | 4 (36.4%) | 4 (33.3%) |
No | 7 (63.6%) | 8 (66.7%) |
PFS, median (range, days) | 345 (301-720) | 208 (93-260) |
Duration of bevacizumab treatment, median, days, range | 363 (138-880) | 207 (83-460) |